Exhibit 99.1
Aurinia Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
VICTORIA, British Columbia--(BUSINESS WIRE)--October 19, 2015--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its Chief Operating Officer, Michael R. Martin will present a corporate overview of the company at the 14th annual BIO Investor Forum, taking place October 20th – 21st in San Francisco at the Parc 55 San Francisco Hotel. The presentation will also be available using the webcast link below.
|
Aurinia Presentation Details |
|||
| Date: | Wednesday, October 21st, 2015 | ||
| Time: | 11:00 a.m. Pacific Standard Time | ||
| Location: | Fillmore Room | ||
| Webcast: | http://www.veracast.com/webcasts/bio/investorforum2015/37207102862.cfm | ||
About Aurinia
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently in the recruitment and enrollment phase of its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis (LN). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information.
CONTACT:
Aurinia Pharmaceuticals
Company:
Stephen
Zaruby, 250-708-4293
President & Chief Executive Officer
szaruby@auriniapharma.com
or
Investor
& Media:
Michael R. Martin, 250-708-4272
Chief Operating
Officer
mmartin@auriniapharma.com